Targeted lung denervation

InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing

Retrieved on: 
Tuesday, February 14, 2023
EPS, TEL, TCAR, Targeted lung denervation, Cordis, Cardinal Health, Marketing, Global marketing, Clinical trial, IDE, COPD, Stroke, FDA, Growth, KOL, NSPR, Management

TEL AVIV, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired medical device commercial veteran Shane Gleason as General Manager of North America and Vice President of Global Marketing.

Key Points: 
  • TEL AVIV, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired medical device commercial veteran Shane Gleason as General Manager of North America and Vice President of Global Marketing.
  • Mr. Gleason brings to InspireMD significant expertise in vascular interventions and a track record of successful go-to-market execution.
  • His knowledge of the carotid market, reputation with our key opinion leader (KOL) partners and track record of successfully executing new product launches globally add tremendous capabilities to our senior team.
  • Earlier in his career, Mr. Gleason held sales and marketing leadership roles at Cordis, a Cardinal Health company, Trivascular Technologies (part of Endologix), and Abbott Vascular, where he launched the second FDA approved carotid stent system.

Broncus (02216.HK) announced interim results

Retrieved on: 
Wednesday, August 31, 2022
Lung cancer, University, Technology, Safety, Diagnosis, Degenerative disease, R, Sale, RFA, Tissue, Conditional sentence, USD, National Medical Products Administration, Chronic obstructive pulmonary disease, Laboratory, Hospital, NMPA, Patent, Targeted lung denervation, TLD, IIA, FDA, COPD, CE, Marketing, Patient, Renewable energy, Medical device, Pharmaceutical industry, Medical imaging, Bronchus, EU

HANGZHOU, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, 2022, Broncus (02216.HK), the leader in the field of interventional pulmonology in China, reported its interim result for the six months ended June 30, 2022 (the "Reporting Period").

Key Points: 
  • Broncus has comprehensive pipelines in interventional diagnosis and treatment of lung diseases and leads the market of medical devices for pulmonary interventional.
  • Among them, Broncus have completed the First In Man clinical trial for Targeted Lung Denervation (TLD) Radiofrequency Ablation System.
  • In July 2022, Broncus have completed the product design and submit the type examination of InterVapor for Lung Cancer.
  • The core strength of Broncus can be further enhanced and more innovative technologies can be brought to patients with lung diseases all over the world.

Fortem IP LLP Welcomes Veteran Intellectual Property Attorney Jeff Grainger

Retrieved on: 
Friday, January 7, 2022
Initial public offering, JD, View, University of Washington Department of Bioengineering, University, Electronics, Acquisition, Jeff, General counsel, Topical steroid withdrawal, Software, Mechanical engineering, Mechanical, Robotics, IP, Targeted lung denervation, Abbott Laboratories, Patent, Genomics, Foundry, Heart failure, Fortune 500, BS, Multimedia, Biotechnology, Degenerative disease, 3D printing, Management, Financial services, Stanford University, Counsel

SEATTLE, Jan. 7, 2022 /PRNewswire/ -- We are thrilled to announce that Jeff Grainger has joined the Fortem IP team as Of Counsel.

Key Points: 
  • SEATTLE, Jan. 7, 2022 /PRNewswire/ -- We are thrilled to announce that Jeff Grainger has joined the Fortem IP team as Of Counsel.
  • Jeff's unparalleled track record as a patent attorney (law firm and in-house) general counsel, licensing executive, entrepreneur, board member, and robotics engineer, and the perspective that these unique experiences bring, make Jeff a valuable asset for Fortem IP and our clients.
  • Jeff holds a JD with Honors from the University of Washington and a BS in Mechanical Engineering from Stanford.
  • Fortem IP was founded to provide legal counsel that aligns intellectual property strategy with business strategy for innovative companies of all shapes and sizes, from start-ups and venture firms to Fortune 500 companies.

Imperative Care Appoints Three to Its Board of Directors

Retrieved on: 
Friday, August 20, 2021
Cardiology, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Hospitals, Other Health, The Cooper Companies, Industry, Columbia University, University, Johnson & Johnson, Moyamoya disease, Acquisition, Cornell University, The Blackstone Group, D1, Board, Targeted lung denervation, Partner, Donaldson, Commerce, Credit Suisse, Investment, NYSE, IPO, NASDAQ, UBS, D1 Capital Partners, Foundry, Housing, Communities and Local Government Committee, Abbott Laboratories, Patient, Solution, Donaldson, Lufkin & Jenrette, CEO, Trustee, The, Stroke, Woman, Director, Management

Imperative Care, Inc. today announced three appointments to the companys Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers.

Key Points: 
  • Imperative Care, Inc. today announced three appointments to the companys Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers.
  • Holly, Hank and James will further strengthen the tremendous prowess of the existing Imperative Care Board, to help achieve this important mission.
  • We are delighted to have them on the team, said John Hamre, Ph.D., Chairman of the Nominating and Governance Committee of the Imperative Cares Board of Directors.
  • Imperative Care and Truvic Medical are based in Campbell, Calif.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005043/en/

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Retrieved on: 
Monday, June 8, 2020
Respiratory diseases, Pulmonology, Medicine, Chronic lower respiratory diseases, Respiratory therapy, Chronic obstructive pulmonary disease, Targeted lung denervation, Obstructive lung disease, Denervation, Acute exacerbation of chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease

MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).
  • Nuvaira's lung denervation system is designed to reduce the risk of moderate-to-severe COPD exacerbations in patients on optimal medical care.
  • Nuvaira also announces appointment of Tim Herbert, President & CEO of Minneapolis-based Inspire Medical Systems to its Board of Directors.
  • Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/nuvaira-announces-fda-breakthrou...

Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

Retrieved on: 
Monday, February 11, 2019
Medicine, Organ systems, Pulmonology, Asthma, Targeted lung denervation, Pulmonary function testing, Denervation, Chronic obstructive pulmonary disease, Bronchial hyperresponsiveness, Lung, Respiratory tract, Respiratory disease

Nuvaira's Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma in a procedure called Targeted Lung Denervation (TLD).

Key Points: 
  • Nuvaira's Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma in a procedure called Targeted Lung Denervation (TLD).
  • Nuvaira is the first interventional pulmonary company to pursue and report one-year randomized, double-blinded and sham-controlled clinical evidence in COPD patients from a Phase 2b trial.
  • The company has developed the Nuvaira Lung Denervation System to address chronic lung diseases by treating the overactive airway nerves with Targeted Lung Denervation (TLD).
  • The Nuvaira Lung Denervation System is under clinical investigation and is not commercially available in the USA.